Pelthos Therapeutics (NYSEAMERICAN:PTHS) Director Todd Davis Buys 35,948 Shares

Pelthos Therapeutics Inc. (NYSEAMERICAN:PTHS) Director Todd Davis bought 35,948 shares of the firm’s stock in a transaction on Thursday, June 11th. The shares were purchased at an average cost of $27.82 per share, with a total value of $1,000,073.36. Following the completion of the transaction, the director owned 75,834 shares in the company, valued at $2,109,701.88. This represents a 90.13% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Pelthos Therapeutics Stock Down 3.6%

Shares of NYSEAMERICAN PTHS opened at $26.50 on Tuesday. The company has a current ratio of 2.79, a quick ratio of 1.86 and a debt-to-equity ratio of 1.41. The firm’s fifty day moving average price is $25.22. The company has a market cap of $92.22 million, a price-to-earnings ratio of -1.28 and a beta of 3.17. Pelthos Therapeutics Inc. has a twelve month low of $11.20 and a twelve month high of $54.29.

Pelthos Therapeutics (NYSEAMERICAN:PTHS) last issued its earnings results on Thursday, May 14th. The company reported ($3.09) earnings per share for the quarter. The business had revenue of $10.91 million during the quarter. On average, research analysts expect that Pelthos Therapeutics Inc. will post -11.7 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in PTHS. Persistent Asset Partners Ltd increased its position in Pelthos Therapeutics by 150.0% during the 4th quarter. Persistent Asset Partners Ltd now owns 6,007 shares of the company’s stock valued at $186,000 after buying an additional 3,604 shares in the last quarter. Pale Fire Capital SE increased its position in Pelthos Therapeutics by 59.5% during the 1st quarter. Pale Fire Capital SE now owns 12,919 shares of the company’s stock valued at $271,000 after buying an additional 4,819 shares in the last quarter. Millennium Management LLC acquired a new position in Pelthos Therapeutics during the 4th quarter valued at about $343,000. Geode Capital Management LLC increased its position in Pelthos Therapeutics by 31.9% during the 4th quarter. Geode Capital Management LLC now owns 13,625 shares of the company’s stock valued at $422,000 after buying an additional 3,295 shares in the last quarter. Finally, Knott David M Jr increased its position in Pelthos Therapeutics by 9.3% during the 1st quarter. Knott David M Jr now owns 21,073 shares of the company’s stock valued at $443,000 after buying an additional 1,792 shares in the last quarter. 77.96% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

PTHS has been the subject of a number of research analyst reports. Piper Sandler began coverage on Pelthos Therapeutics in a research report on Friday, February 27th. They set an “overweight” rating and a $48.00 target price for the company. Oppenheimer lifted their price target on Pelthos Therapeutics from $62.00 to $66.00 and gave the company an “outperform” rating in a report on Friday, May 15th. Roth Mkm cut their price target on Pelthos Therapeutics from $57.00 to $55.00 and set a “buy” rating on the stock in a report on Thursday, February 26th. Cantor Fitzgerald began coverage on Pelthos Therapeutics in a report on Wednesday, April 1st. They issued an “overweight” rating and a $50.00 price target on the stock. Finally, HC Wainwright reiterated a “buy” rating and issued a $60.00 price target on shares of Pelthos Therapeutics in a report on Thursday, March 19th. Five equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to MarketBeat, Pelthos Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $55.80.

Pelthos Therapeutics Company Profile

We are a clinical-stage biotech company focused on developing and commercializing new therapeutics to alleviate pain. Our clinical focus is to selectively target the sodium ion-channel known as “NaV1.7”, as well as other receptors in the NaV family. NaV1.7 has been genetically validated as a pain receptor in human physiology. Genetic studies have shown that families with a certain inherited NaV1.7 modulation consistently show a pathology of not feeling pain. A NaV1.7 blocker is a chemical entity that modulates the structure of the sodium-channel in a way to prevent the transmission of pain perception to the central nervous system (“CNS”).